JAK 阻害薬と悪性腫瘍リスク: さまざまな疾患のメタ解析
Ann Rheum Dis. 2023;82(8):1059–1067 doi: 10.1136/ard-2023-224049
The objective of this study was to estimate the association of JAKi with the incidence of malignancy, compared with placebo, TNFi and MTX.
June 2023
November 2019
関節リウマチにおける低分子JAK阻害薬の感染リスクに関す るシステマティックレビューとメタ解析
Rheumatology (Oxford) 2019;58(10):1755–66
Absolute serious infection rates were low. However, across the JAKinibs, the incidence of HZ is higher than expected for the population. While the risk was numerically greatest with BARI, indirect comparisons between the drugs did not demonstrate any significant difference in risk. How JAKinibs increase the risk of HZ reactivation is unclear, but how different JAKs interact in the immune response suggest that there may be differences in safety profiles between JAKinib drugs, underpinned by their...
May 2019
関節リウマチにおける低分子JAK阻害薬の感染リスクに関す るシステマティックレビューとメタ解析
Rheumatology (Oxford). DOI: 10.1093/rheumatology/kez087
How JAKinibs increase the risk of HZ reactivation is unclear. Roles of different JAKs in the immune response may suggest differences in safety profiles between drugs, underpinned by their differential JAK selectivity profiles. The authors undertook a systematic review and meta-analysis to evaluate SI and opportunistic indicator infections including HZ in RA Phase II/III clinic trials with JAKinibs. A literature review of RCT of TOF (5 mg BID), BARI (4 mg OD) and UPA (15 mg OD) was conducted. A p...